NASA’s Europa Clipper began its journey to study Jupiter’s moon Europa. SpaceX’s Starship achieved its first successful landing, a critical milestone for future deep space missions. China made headlines with the Chang’e 6 mission, which successfully returned samples from the far side of the Moon. Meanwhile, the International Space Station continued to host international crews, including private missions like Axiom Mission 3.
As an aerospace engineer, I’m excited for 2025, when space agencies worldwide are gearing up for even more ambitious goals. Here’s a look at the most exciting missions planned for the coming year, which will expand humanity’s horizons even further, from the Moon and Mars to asteroids and beyond:
Scouting the lunar surface with CLPS
NASA’s Commercial Lunar Payload Services, or CLPS, initiative aims to deliver science and technology payloads to the Moon using commercial landers. CLPS is what brought Intuitive Machines’ Odysseus lander to the Moon in February 2024, marking the first U.S. Moon landing since Apollo.
These missions will carry a variety of scientific instruments and technology demonstrations to different lunar locations. The payloads will include experiments to study lunar geology, test new technologies for future human missions and gather data on the Moon’s environment.
Surveying the sky with SPHEREx
In February 2025, NASA plans to launch the Spectro-Photometer for the History of the Universe, Epoch of Reionization and Ices Explorer, or SPHEREx, observatory. This mission will survey the sky in near-infrared light, which is a type of light that is invisible to the naked eye but that special instruments can detect. Near-infrared light is useful for observing objects that are too cool or too distant to be seen in visible light.
SPHEREx will create a comprehensive map of the universe by surveying and collecting data on more than 450 million galaxies along with over 100 million stars in the Milky Way. Astronomers will use this data to answer big questions about the origins of galaxies and the distribution of water and organic molecules in stellar nurseries – where stars are born from gas and dust.
Studying low Earth orbit with Space Rider
The European Space Agency, or ESA, plans to conduct an orbital test flight of its Space Rider uncrewed spaceplane in the third quarter of 2025. Space Rider is a reusable spacecraft designed to carry out various scientific experiments in low Earth orbit.
These scientific experiments will include research in microgravity, which is the near-weightless environment of space. Scientists will study how plants grow, how materials behave and how biological processes occur without the influence of gravity.
Advertisement
Space Rider will also demonstrate new technologies for future missions. For example, it will test advanced telecommunication systems, which are crucial for maintaining communication with spacecraft over long distances. It will also test new robotic exploration tools for use on future missions to the Moon or Mars.
Exploring the Moon with M2/Resilience
Japan’s M2/Resilience mission, scheduled for January 2025, will launch a lander and micro-rover to the lunar surface.
This mission will study the lunar soil to understand its composition and properties. Researchers will also conduct a water-splitting test to produce oxygen and hydrogen by extracting water from the lunar surface, heating the water and splitting the captured steam. The generated water, oxygen and hydrogen can be used for enabling long-term lunar exploration.
This mission will also demonstrate new technologies, such as advanced navigation systems for precise landings and systems to operate the rover autonomously. These technologies are essential for future lunar exploration and could be used in missions to Mars and beyond.
China’s Tianwen-2 mission is an ambitious asteroid sample return and comet probe mission. Scheduled for launch in May 2025, Tianwen-2 aims to collect samples from a near-Earth asteroid and study a comet. This mission will advance scientists’ understanding of the solar system’s formation and evolution, building on the success of China’s previous lunar and Mars missions.
The mission’s first target is the near-Earth asteroid 469219 Kamoʻoalewa. This asteroid is a quasi-satellite of Earth, meaning it orbits the Sun but stays close to Earth. Kamoʻoalewa is roughly 131-328 feet (40-100 meters) in diameter and may be a fragment of the Moon, ejected into space by a past impact event.
By studying this asteroid, scientists hope to learn about the early solar system and the processes that shaped it. The spacecraft will use both touch-and-go and anchor-and-attach techniques to collect samples from the asteroid’s surface.
After collecting samples from Kamoʻoalewa, Tianwen-2 will return them to Earth and then set course for its second target, the main-belt comet 311P/PANSTARRS. This comet is located in the asteroid belt between Mars and Jupiter.
By analyzing the comet’s materials, researchers hope to learn more about the conditions that existed in the early solar system and possibly the origins of water and organic molecules on Earth.
Solar system flybys
Besides the above planned launch missions, several space agencies plan to perform exciting deep-space flyby missions in 2025.
Advertisement
A flyby, or gravity assist, is when a spacecraft passes close enough to a planet or moon to use its gravity for a speed boost. As the spacecraft approaches, it gets pulled in by the planet’s gravity, which helps it accelerate.
After swinging around the planet, the spacecraft is flung back out into space, allowing it to change direction and continue on its intended path using less fuel. https://www.youtube.com/embed/0iAGrdITIiE?wmode=transparent&start=0 Spacecraft can fly by a planet to get a boost using gravity.
BepiColombo, a joint mission by ESA and the Japan Aerospace Exploration Agency, JAXA, will make its sixth flyby of Mercury in January 2025. This maneuver will help the spacecraft enter orbit around Mercury by November 2026. BepiColombo aims to study Mercury’s composition, atmosphere and surface geology.
NASA’s Europa Clipper mission, which launched in October 2024, will make significant progress on its journey to Jupiter’s moon Europa. In March 2025, the spacecraft will perform a flyby maneuver at Mars.
This maneuver will help the spacecraft gain the necessary speed and trajectory for its long voyage. Later in December 2026, Europa Clipper will perform a flyby of Earth, using Earth’s gravity to further increase its momentum so it can arrive at Europa in April 2030.
The ESA’s Hera mission will also perform a flyby of Mars in March 2025. Hera is part of the Asteroid Impact and Deflection Assessment mission, which plans to study the Didymos binary asteroid system. The mission will provide valuable data on asteroid deflection techniques and contribute to planetary defense strategies.
NASA’s Lucy mission will continue its journey to explore the Jupiter Trojan asteroids, which share Jupiter’s orbit around the Sun, in 2025. One key event for Lucy is its flyby of the inner main-belt asteroid 52246 Donaldjohanson, scheduled for April 20, 2025.
This flyby will provide valuable data on this ancient asteroid’s composition and surface features, which can help researchers gain insights into the early solar system. The asteroid is named after the paleoanthropologist who discovered the famous “Lucy” fossil.
ESA’s Jupiter Icy Moons Explorer, or JUICE, mission will perform a Venus flyby in August 2025. This maneuver will help JUICE gain the necessary speed and trajectory for its journey to Jupiter. Once it arrives, JUICE will study Jupiter’s icy moons to understand their potential for harboring life.
2025 promises to be a groundbreaking year for space exploration. With NASA’s ambitious missions and significant contributions from other countries, we are set to make remarkable strides in humanity’s understanding of the universe. These missions will not only advance scientific knowledge but also inspire future generations to look to the stars.
Harkins Theatres Announces Rob Reiner Tribute Screening of The American President
Harkins Theatres has announced a special one-day tribute screening honoring acclaimed filmmaker Rob Reiner, celebrating his life’s work and cinematic legacy.
On December 17, select Harkins locations will screen Reiner’s 1995 political romance The American President, with all proceeds benefiting the Human Rights Campaign. Tickets are priced at $5, making the event both an accessible film experience and a charitable fundraiser.
The tribute was announced via Harkins’ official, verified social media accounts and is positioned as a legacy celebration, not a memorial.
🎥 Why The American President?
Released in 1995 and written by Aaron Sorkin, The American President stars Michael Douglas and Annette Bening and remains one of Rob Reiner’s most politically resonant films. The movie blends romance, idealism, and civic responsibility — themes that have consistently appeared throughout Reiner’s career.
The film later served as a creative blueprint for The West Wing, cementing its place in modern political storytelling.
Rob Reiner’s career spans more than five decades, including landmark films such as:
This Is Spinal Tap
Stand By Me
The Princess Bride
When Harry Met Sally…
Misery
A Few Good Men
His work is often praised for balancing entertainment, empathy, and social conscience, making tribute events like this especially meaningful to longtime audiences.
Hollywood Legend Rob Reiner and Wife Found Dead; Son in Custody
Renowned filmmaker Rob Reiner and his wife, Michele Singer Reiner, were found dead in their Los Angeles home in a reported homicide. Police have arrested their son in connection with the case, and tributes are pouring in.
Director Rob Reiner participates in a discussion following a screening of the film LBJ at the LBJ Presidential Library in Austin, Texas on Saturday October 22, 2016 On Saturday evening October 22, 2016, the LBJ Presidential Library held a sneak peek of Rob Reiner’s new filmÊLBJ, starring Woody Harrelson as the 36th president. The film, which premiered at the Toronto International Film Festival in September, chronicles the life and times of Lyndon Johnson who would inherit the presidency at one of the most fraught moments in American history. Following the screening, director Rob Reiner, actor Woody Harrelson, and writer Joey Hartstone joined LBJ Library Director Mark Updegrove on stage for a conversation about the film. LBJ Library photo by Jay Godwin 10/22/2016
Hollywood Legend Rob Reiner and Wife Found Dead; Son in Custody
December 15, 2025
Renowned filmmaker and actor Rob Reiner, 78, and his wife Michele Singer Reiner, 68, were found dead in their Brentwood, Los Angeles home on Sunday, authorities say. Emergency responders were called to the residence Sunday afternoon, where both were discovered with fatal wounds consistent with a stabbing. Police are treating the case as a double homicide.
Los Angeles police arrested the couple’s 32-year-old son, Nick Reiner, in connection with the deaths. He is being held in custody as investigators continue to piece together the circumstances surrounding the incident.
2016 SAMHSA Voice Awards
Reiner was one of Hollywood’s most influential figures, known for his work as a director, producer and actor. His career spanned decades, from early television fame to directing beloved films that shaped American cinema.
Friends, colleagues and public figures have begun sharing tributes and reactions to the news as the investigation is ongoing.
More details will be updated as they become available.
FDA’s COVID-19 Vaccine Safety Claims Lack Solid Evidence—Why Overreaction Could Harm Public Health
COVID-19 vaccine safety: The FDA’s claims about COVID-19 vaccine deaths in children lack strong evidence and could restrict vaccine access. Learn why experts say VAERS reports aren’t proof, and how overreacting may harm public health and trust in vaccines.
The death of children due to an unsafe vaccine is a serious allegation. I am a pediatric cardiologist who has studied the link between COVID-19 vaccines and heart-related side effects such as myocarditis in children. To my knowledge, studies to date have shown such side effects are rare, and severe outcomes even more so. However, I am open to new evidence that could change my mind. But without sufficient justification and solid evidence, restricting access to an approved vaccine and changing well-established procedures for testing vaccines would carry serious consequences. These moves would limit access for patients, create roadblocks for companies and worsen distrust in vaccines and public health. In my view, it’s important for people reading about these FDA actions to understand how the evidence on a vaccine’s safety is generally assessed.
Determining cause of death
The FDA memo claims that the deaths of these children were directly related to receiving a COVID-19 immunization. From my perspective as a clinician, it is awful that any child should die from a routine vaccination. However, health professionals like me owe it to the public to uphold the highest possible standards in investigating why these deaths occurred. If the FDA has evidence demonstrating something that national health agencies worldwide have missed – widespread child deaths due to myocarditis caused by the COVID-19 vaccine – I don’t doubt that even the most pro-vaccine physician will listen. So far, however, no such evidence has been presented. While a death logged in VAERS is a starting point, on its own it is insufficient to conclude whether a vaccine caused the death or other medical causes were to blame. To demonstrate a causal link, FDA staff and physicians must align the VAERS report with physicians’ assessments of the patient, as well as data from other sources for monitoring vaccine safety. These include PRISM, which logs insurance claims data, and the Vaccine Safety Datalink, which tracks safety signals in electronic medical records. It’s known that most deaths logged only in VAERS of children who recently received vaccines have been incorrectly attributed to the vaccines – either by accident or in some cases on purpose by anti-vaccine activists.
Heart-related side effects of COVID-19 vaccines
In his Substack and Twitter accounts, Prasad has said that he believes the rate of severe cardiac side effects after COVID-19 vaccination is severely underestimated and that the vaccines should be restricted far more than they currently are. In a July 2025 presentation, Prasad quoted a risk of 27 cases per million of myocarditis in young men who received the COVID-19 vaccine. A 2024 review suggested that number was a bit lower – about 20 cases out of 1 million people. But that same study found that unvaccinated people had greater risk of heart problems after a COVID-19 infection than vaccinated people. In a different study, people who got myocarditis after a COVID-19 vaccination developed fewer complications than people who got myocarditis after a COVID-19 infection. Existing vaccine safety infrastructure in the U.S. successfully identifies dangers posed by vaccines – and did so during the COVID-19 pandemic. Today, most COVID-19 vaccines in the U.S. rely on mRNA technology. But as vaccines were first emerging during the COVID-19 pandemic, two pharmaceutical companies, Janssen and AstraZeneca, rolled out a vaccine that used a different technology, called a viral vector. This type of vaccine had a very rare but genuine safety problem that was detected.A report in VAERS is at most a first step to determining whether a vaccine caused harm. VAERS, the Vaccine Safety Datalink, clinical investigators in the U.S. and their European counterparts detected that these vaccines did turn out to cause blood clotting. In April 2021, the FDA formally recommended pausing their use, and they were later pulled from the market. Death due to myocarditis from COVID-19 vaccination is exceedingly rare. Demonstrating that it occurred requires proof that the person had myocarditis, evidence that no other reasonable cause of death was present, and the absence of any additional cause of myocarditis. These factors cannot be determined from VAERS data, however – and to date, the FDA has presented no other relevant data.
A problematic vision for future vaccine approvals
Currently, vaccines are tested both by seeing how well they prevent disease and by how well they generate antibodies, which are the molecules that help your body fight viruses and bacteria. Some vaccines, such as the COVID-19 vaccine and the influenza vaccine, need to be updated based on new strains. The FDA generally approves these updates based on how well the new versions generate antibodies. Since the previous generation of vaccines was already shown to prevent infection, if the new version can generate antibodies like the previous one, researchers assume its ability to prevent infection is comparable too. Later studies can then test how well the vaccines prevent severe disease and hospitalization. The FDA memo says this approach is insufficient and instead argues for replacing such studies with many more placebo-controlled trials – not just for COVID-19 vaccines but also for widely used influenza and pneumonia vaccines. That may seem reasonable theoretically. In practice, however, it is not realistic. Today’s influenza vaccines must be changed every season to reflect mutations to the virus. If the FDA were to require new placebo-controlled trials every year, the vaccine being tested would become obsolete by the time it is approved. This would be a massive waste of time and resources.Influenza vaccines must be updated for every flu season.Jacob Wackerhausen/iStock via Getty Images Plus Also, detecting vaccine-related myocarditis at the low rate at which it occurs would have required clinical trials many times larger than the ones that were done to approve COVID-19 mRNA vaccines. This would have cost at least millions of dollars more, and the delay in rolling out vaccines would have also cost lives. Placebo-controlled trials would require comparing people who receive the updated vaccine with people who remain unvaccinated. When an older version of the vaccine is already available, this means purposefully asking people to forgo that vaccine and risk infection for the sake of the trial, a practice that is widely considered unethical. Current scientific practice is that only a brand-new vaccine may be compared against placebo. While suspected vaccine deaths should absolutely be investigated, stopping a vaccine for insufficient reasons can lead to a significant drop in public confidence. That’s why it’s essential to thoroughly and transparently investigate any claims that a vaccine causes harm.
